Go Pro
NASDAQ:JBIO

Jade Biosciences Q3 2025 Earnings Report

Jade Biosciences logo
$17.89 -1.25 (-6.53%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$17.90 +0.01 (+0.06%)
As of 09/11/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Jade Biosciences EPS Results

Actual EPS
-$0.48
Consensus EPS
-$0.57
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

Jade Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Jade Biosciences Announcement Details

Quarter
Q3 2025
Time
After Market Closes
Conference Call Date
Friday, November 14, 2025
Conference Call Time
7:00AM ET

Jade Biosciences Earnings Headlines

Jade Biosciences (NASDAQ:JBIO) Stock Rating Lowered by Wall Street Zen
Jade Biosciences to Participate in Upcoming Conferences
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
Jade Biosciences: Duration Is The Real Product
Jade Biosciences Inc JBIO
See More Jade Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Jade Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jade Biosciences and other key companies, straight to your email.

About Jade Biosciences

Jade Biosciences (NASDAQ:JBIO) (NASDAQ: JBIO) is a clinical-stage biotechnology company focused on developing medicines for autoimmune and inflammatory diseases. The company uses antibody-based drug discovery and development approaches to pursue therapies intended to address significant unmet medical needs.

Jade Biosciences is advancing a pipeline of investigational programs and does not currently have commercially marketed products. Its work is centered on identifying and developing targeted therapies that may modulate biological pathways involved in autoimmune disease.

The company’s activities primarily consist of research, preclinical development and clinical evaluation of its drug candidates. As an early-stage biotechnology company, its programs remain subject to development, regulatory and clinical risks, and the timing of potential product launches is uncertain.

View Jade Biosciences Profile